Teva to pay $1.2bn in FTC ‘pay-for-delay’ case

29-05-2015

Teva to pay $1.2bn in FTC ‘pay-for-delay’ case

Photo: Teva

Israel-based pharmaceutical company Teva will have to fork out $1.2 billion after a long-running dispute with the US Federal Trade Commission (FTC) over a controversial ‘pay-for-delay’ case was settled.


Teva, Cephalon, FTC, generics, pay-for-delay, Federal Trade Commission

LSIPR